Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VC9V
|
|||
| Drug Name |
2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1
|
|||
| Synonyms |
PMID26560530-Compound-36
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Dongguk University Industry-Academic Cooperation Foundation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20N4O
|
|||
| Canonical SMILES |
C1CCN(C1)CCOC2=NC3=C(N=CC=C3)N=C2C#CC4=CC=CC=C4
|
|||
| InChI |
1S/C21H20N4O/c1-2-7-17(8-3-1)10-11-19-21(26-16-15-25-13-4-5-14-25)24-18-9-6-12-22-20(18)23-19/h1-3,6-9,12H,4-5,13-16H2
|
|||
| InChIKey |
MNYJJHBAEYKXEG-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.